PL3783011T3 - Aktywacja bioluminescencji przez dopełnienie strukturalne - Google Patents

Aktywacja bioluminescencji przez dopełnienie strukturalne

Info

Publication number
PL3783011T3
PL3783011T3 PL20197758.4T PL20197758T PL3783011T3 PL 3783011 T3 PL3783011 T3 PL 3783011T3 PL 20197758 T PL20197758 T PL 20197758T PL 3783011 T3 PL3783011 T3 PL 3783011T3
Authority
PL
Poland
Prior art keywords
bioluminescence
activation
structural complementation
complementation
structural
Prior art date
Application number
PL20197758.4T
Other languages
English (en)
Polish (pl)
Inventor
Andrew S. Dixon
Lance P. Encell
Mary P. Hall
Keith V. Wood
Monika G. Wood
Marie SCHWINN
Brock Binkowski
Hicham Zegzouti
Nidhi Nath
Subhanjan Mondal
Said Goueli
Poncho Meisenheimer
Thomas Kirkland
James Unch
Dileep K. Pulukkunat
Matthew B. Robers
Melanie Dart
Thomas Machleidt
Original Assignee
Promega Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corporation filed Critical Promega Corporation
Publication of PL3783011T3 publication Critical patent/PL3783011T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0283—Price estimation or determination
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Recommending goods or services
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/02—Services making use of location information
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/35—Services specially adapted for particular environments, situations or purposes for the management of goods or merchandise
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
    • H04W4/30—Services specially adapted for particular environments, situations or purposes
    • H04W4/38—Services specially adapted for particular environments, situations or purposes for collecting sensor information
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Finance (AREA)
  • Accounting & Taxation (AREA)
  • Development Economics (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Theoretical Computer Science (AREA)
  • General Business, Economics & Management (AREA)
  • Marketing (AREA)
  • Economics (AREA)
  • Veterinary Medicine (AREA)
PL20197758.4T 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne PL3783011T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791549P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PL3783011T3 true PL3783011T3 (pl) 2022-11-21

Family

ID=51581027

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20197758.4T PL3783011T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne
PL14769752.8T PL2970412T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14769752.8T PL2970412T3 (pl) 2013-03-15 2014-03-13 Aktywacja bioluminescencji przez dopełnienie strukturalne

Country Status (15)

Country Link
US (11) US9797889B2 (OSRAM)
EP (4) EP4169935A1 (OSRAM)
JP (4) JP6654557B2 (OSRAM)
KR (3) KR20230079494A (OSRAM)
CN (2) CN105143249A (OSRAM)
AU (3) AU2014236949C1 (OSRAM)
BR (1) BR112015023394B8 (OSRAM)
CA (1) CA2906063C (OSRAM)
DK (2) DK2970412T5 (OSRAM)
ES (2) ES2926463T3 (OSRAM)
IL (3) IL286816B (OSRAM)
PL (2) PL3783011T3 (OSRAM)
PT (2) PT3783011T (OSRAM)
SG (2) SG10201601929YA (OSRAM)
WO (1) WO2014151736A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9797889B2 (en) 2013-03-15 2017-10-24 Promega Corporation Activation of bioluminescence by structural complementation
EP3191601B1 (en) * 2014-09-12 2022-11-02 Promega Corporation Internal protein tags
US11365402B2 (en) 2014-09-12 2022-06-21 Promega Corporation Internal protein tags
EP3254113B1 (en) * 2015-02-05 2024-10-09 Promega Corporation Luciferase-based thermal shift assays
US10634680B2 (en) 2016-04-26 2020-04-28 University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
MX2019004431A (es) 2016-10-20 2019-08-14 Harvard College Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas.
CA3022981C (en) * 2017-11-01 2025-05-06 Queen's University At Kingston HIPPO BIOLUMINOUS TRAIL BIOSENSOR
WO2019164402A1 (en) * 2018-02-26 2019-08-29 Technische Universiteit Eindhoven Bioluminescent biosensor for detecting and quantifying biomolecules
EP4140991B1 (en) 2018-06-01 2024-05-15 Promega Corporation Inhibitors of oplophorus luciferase-derived bioluminescent complexes
US20200270586A1 (en) * 2018-06-12 2020-08-27 Promega Corporation Multipartite luciferase
US10962538B2 (en) 2018-06-14 2021-03-30 The Trustees Of Columbia University In The City Of New York Assays using arrestin recruitment and unmodified receptors
CA3114424A1 (en) 2018-10-03 2020-04-09 Promega Corporation Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof
WO2020113036A2 (en) 2018-11-28 2020-06-04 Promega Corporation Reactive peptide labeling
EP3891503A2 (en) 2018-12-04 2021-10-13 Promega Corporation Broad spectrum gpcr binding agents
EP3941195A4 (en) 2019-03-20 2023-03-22 Promega Corporation PHOTOAFFINITY PROBES
CA3135195A1 (en) * 2019-04-10 2020-10-15 Promega Corporation Compositions and methods for analyte detection using bioluminescence
US11360096B2 (en) 2019-05-16 2022-06-14 Duke University Complex BRET technique for measuring biological interactions
AU2020308448A1 (en) 2019-06-24 2022-02-03 Promega Corporation Modified polyamine polymers for delivery of biomolecules into cells
DE102019127894B4 (de) * 2019-10-16 2022-05-12 Sensor-Instruments Entwicklungs- Und Vertriebs-Gmbh Produktkennzeichnungssystem und verfahren zur kennzeichnung eines produkts
WO2021102434A1 (en) * 2019-11-22 2021-05-27 The Regents Of The University Of California Split-enzyme system to detect specific dna in living cells
WO2021108765A1 (en) 2019-11-27 2021-06-03 Promega Corporation Multipartite luciferase peptides and polypeptides
US12061202B2 (en) 2019-12-10 2024-08-13 Promega Corporation Compositions and methods for bioluminescent detection using multifunctional probes
EP4127148A1 (en) 2020-03-25 2023-02-08 Erasmus University Rotterdam Medical Center Reporter system for radionuclide imaging
WO2021231498A2 (en) * 2020-05-11 2021-11-18 Chan Zuckerberg Biohub, Inc. Detection assay for anti-sars-cov-2 antibodies
JP7677997B2 (ja) 2020-05-22 2025-05-15 プロメガ コーポレイション キナーゼターゲットエンゲージメントの増強
CN116391129A (zh) 2020-08-28 2023-07-04 普罗美加公司 针对ras蛋白的靶标接合测定法
US20240252689A1 (en) * 2021-05-18 2024-08-01 The Board Of Regents Of The University Of Texas System Poly-adp ribose (par) tracker optimized split-protein reassembly par detection reagents
US20240191211A1 (en) 2022-05-04 2024-06-13 Promega Corporation Bioluminescence-triggered photocatalytic labeling
JP2025515181A (ja) 2022-05-04 2025-05-13 プロメガ コーポレイション 伸長表面ループ領域を有する修飾デハロゲナーゼ
EP4519290A1 (en) 2022-05-04 2025-03-12 Promega Corporation Circularly permuted dehalogenase variants
JP2025516354A (ja) 2022-05-04 2025-05-27 プロメガ コーポレイション スプリット修飾デハロゲナーゼバリアント
WO2024151471A1 (en) 2023-01-09 2024-07-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-throughput assay based on ligand-biased structural dynamics response
CN121057740A (zh) * 2023-04-21 2025-12-02 深圳琅技生命科技有限公司 一种肽以及含有该肽的发光复合物
US20240368565A1 (en) * 2023-05-04 2024-11-07 Promega Corporation Complementation-based tags and reporters for dual-modality labeling
WO2025064581A1 (en) * 2023-09-18 2025-03-27 The Brigham And Women’S Hospital, Inc. Biosensor platform for the rapid detection of analytes
WO2025158412A1 (en) 2024-01-26 2025-07-31 Biohaven Therapeutics Ltd. BIFUNCTIONAL DEGRADERS OF IgG4 IMMUNOGLOBULINS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US5914095A (en) 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5756688A (en) 1992-10-14 1998-05-26 Sterling Winthrop Inc. MR imaging compositions and methods
ES2105332T3 (es) 1992-10-14 1997-10-16 Nycomed Imaging As Polimeros quelantes.
GB9503969D0 (en) 1995-02-28 1995-04-19 Sams Bernard Incrementing mechanism
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US5879739A (en) 1997-02-20 1999-03-09 Tower Semiconductor Ltd. Batch process for forming metal plugs in a dielectric layer of a semiconductor wafer
DE60142761D1 (de) * 2000-04-26 2010-09-23 Chisso Corp Oplophorus Luciferase
JP4613441B2 (ja) * 2000-04-26 2011-01-19 チッソ株式会社 新規ルシフェラーゼおよび発光蛋白質
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7008642B1 (en) 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
US7195884B2 (en) 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
US20040115814A1 (en) * 2002-09-30 2004-06-17 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
US7237811B1 (en) * 2005-04-20 2007-07-03 Lawrence Barry G Casement window latch assembly
US20090149338A1 (en) 2005-09-30 2009-06-11 Hughes Thomas E System for detecting protein-protein interactions
US7601517B2 (en) 2006-01-10 2009-10-13 Stanford University Split protein self complementing fragments, systems, and methods of use thereof
WO2007132461A2 (en) 2006-05-11 2007-11-22 Ramot At Tel Aviv University Ltd. Classification of protein sequences and uses of classified proteins
US20090075313A1 (en) 2007-05-04 2009-03-19 Stanford University Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems
WO2009058364A1 (en) 2007-11-01 2009-05-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Cell-free methods for detecting protein-ligand interctions
WO2009065002A1 (en) * 2007-11-15 2009-05-22 Endocyte, Inc. Method of administering conjugates
WO2010090319A1 (ja) 2009-02-09 2010-08-12 チッソ株式会社 セレンテラジン類縁体及びその製造方法
WO2010119721A1 (ja) 2009-04-17 2010-10-21 独立行政法人産業技術総合研究所 超高輝度で安定な人工生物発光酵素
EP2456864B1 (en) * 2009-05-01 2015-11-11 Promega Corporation Synthetic oplophorus luciferases with enhanced light output
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
EP3498709B1 (en) 2010-11-02 2025-12-31 Promega Corporation Luciferases from Oplophorus: Novel Coelenterazine Substrates and Their Methods of Use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
PL2932267T3 (pl) * 2012-12-12 2020-10-19 Promega Corporation Rozpoznawanie wiązania czynnego biologicznie środka z celem komórkowym z użyciem wewnątrzkomórkowego rezonansowego przeniesienia energii bioluminescencji
US9797889B2 (en) 2013-03-15 2017-10-24 Promega Corporation Activation of bioluminescence by structural complementation
EP3191601B1 (en) * 2014-09-12 2022-11-02 Promega Corporation Internal protein tags

Also Published As

Publication number Publication date
ES2926463T3 (es) 2022-10-26
BR112015023394B1 (pt) 2023-08-29
JP2023055734A (ja) 2023-04-18
AU2018256548B2 (en) 2020-05-14
JP7532562B2 (ja) 2024-08-13
US20160282340A1 (en) 2016-09-29
IL286816B (en) 2022-09-01
IL240985B (en) 2020-05-31
AU2020213288A1 (en) 2020-08-27
KR20210036422A (ko) 2021-04-02
KR20150129721A (ko) 2015-11-20
US20180196038A1 (en) 2018-07-12
SG11201507306VA (en) 2015-10-29
AU2018256548A1 (en) 2018-11-22
US20230342826A1 (en) 2023-10-26
US20180095074A1 (en) 2018-04-05
PT3783011T (pt) 2022-10-26
US20180306782A1 (en) 2018-10-25
EP3783011B1 (en) 2022-09-21
JP2020097597A (ja) 2020-06-25
US9797889B2 (en) 2017-10-24
US12367513B2 (en) 2025-07-22
PT2970412T (pt) 2022-09-13
IL273989B (en) 2021-10-31
EP2970412A4 (en) 2016-07-27
US11493504B2 (en) 2022-11-08
KR102675860B1 (ko) 2024-06-20
EP4177261A1 (en) 2023-05-10
US20180313825A1 (en) 2018-11-01
US9869670B2 (en) 2018-01-16
JP2024167207A (ja) 2024-12-03
BR112015023394B8 (pt) 2023-09-26
KR20230079494A (ko) 2023-06-07
US20250045806A1 (en) 2025-02-06
US10184936B2 (en) 2019-01-22
SG10201601929YA (en) 2016-04-28
AU2014236949B2 (en) 2018-08-02
DK2970412T3 (da) 2022-08-29
CN117024548A (zh) 2023-11-10
DK2970412T5 (da) 2024-10-14
IL286816A (en) 2021-10-31
US10288605B2 (en) 2019-05-14
US9797890B2 (en) 2017-10-24
WO2014151736A1 (en) 2014-09-25
JP6654557B2 (ja) 2020-02-26
AU2020213288B2 (en) 2022-07-07
BR112015023394A2 (pt) 2017-11-28
US20250022022A1 (en) 2025-01-16
CN105143249A (zh) 2015-12-09
IL273989A (en) 2020-05-31
PL2970412T3 (pl) 2022-11-14
US12366572B2 (en) 2025-07-22
CA2906063A1 (en) 2014-09-25
DK3783011T5 (da) 2024-08-19
CA2906063C (en) 2025-10-07
JP7280842B2 (ja) 2023-05-24
IL240985A0 (en) 2015-11-30
US20200292534A1 (en) 2020-09-17
ES2929362T3 (es) 2022-11-28
AU2014236949C1 (en) 2018-11-29
EP2970412B1 (en) 2022-08-10
AU2014236949A1 (en) 2015-09-24
US10648971B2 (en) 2020-05-12
JP2016519065A (ja) 2016-06-30
US20140348747A1 (en) 2014-11-27
EP2970412A1 (en) 2016-01-20
EP3783011A1 (en) 2021-02-24
EP4169935A1 (en) 2023-04-26
US20140363375A1 (en) 2014-12-11
US10107800B2 (en) 2018-10-23
DK3783011T3 (da) 2022-10-17

Similar Documents

Publication Publication Date Title
IL286816A (en) Activation of biological light emission through structural complementation
EP2971183A4 (en) IMPROVED TEST PROCEDURES
EP3076967A4 (en) Novel methods
EP3047358A4 (en) Determination of an operation
EP2954056A4 (en) NEW MULTISPECIFIC CONSTRUCTIONS
EP2970091A4 (en) Solid forms of treprostinil
EP3032248A4 (en) Biosensor
EP2972944A4 (en) CONTEXTUAL DISCOVERY
EP3014628B8 (en) Process of generating germanium-68
EP3049079A4 (en) Solid forms of ceftolozane
GB201601669D0 (en) Biosensor
PL2970845T3 (pl) Bioreaktor
EP3065728A4 (en) Novel methods
GB201303491D0 (en) Culture of leukemia initiating cells
GB201321838D0 (en) Pulse fermentation
EP3008202A4 (en) Methods for detecting the presence of microbes
EP2971254A4 (en) PROCESS FOR ELECTROLYTIC DECARBOXYLATION OF SUGARS
GB201311313D0 (en) Structural component
PT2981527T (pt) Derivados da luciferina
EP3043646A4 (en) Methods of making 2-halonicotinonitriles
EP3068226A4 (en) Novel methods
GB201309056D0 (en) Biosensor
TWM475821U (en) Structure of mosquito-catch
GB201311222D0 (en) Diaphragm
GB201311015D0 (en) Diaphragm